Evermine 50 EES-1 Study

A study to evaluate safety and performance of the Evermine 50 everolimus Eluting Coronary Stent System (EES) in the treatment of subjects with de novo coronary artery lesions

Study Design

- A prospective, non-randomised, multi-center study
- 140 subjects enrolled at nine clinical centers across India

CTRI Number	CTRI/2017/02/007781
Study Objective	To determine the safety and performance of ultrathin strut biodegradable polymer-coated everolimus-eluting coronary stent in patients with coronary artery disease
Primary Endpoint	Major Adverse Cardiac Events
Secondary Endpoint	Stent Thrombosis

Clinical Sites	Nine clinical centers across India
Sample Size	140 subjects
Follow-up	• Follow-up visits at 1 month, 6 months, 12 months and 24 months • OCT at 6 months and QCA at 9 months
Study duration	Study started in October 2016 Estimated study completion in April 2020

❖ Reference:

1. Clinical Trials Registry – India: CTRI/2017/02/007781
   http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=16395&EncHid=&userName=CTRI/2017/02/007781